Effect of botanical immunomodulators on human CYP3A4 inhibition: Implications for concurrent use as adjuvants in cancer therapy

Integrative Cancer Therapies

Volumn 13, Issue 2, 2014, Pages 167-175

  Patil, Dada ^a   Gautam, Manish ^a   Gairola, Sunil ^b   Jadhav, Suresh ^b   Patwardhan, Bhushan ^c  

^a Research Foundation   (India)

^b Indus Biotech Private Limited   (India)

^c UNIVERSITY OF PUNE   (India)

Author keywords

Asparagus racemosus; botanical immunomodulators; cancer adjuvant; CYP3A4 inhibition; herb drug interactions; Tinospora cordifolia; Withania somnifera

Indexed keywords

ASPARAGUS RACEMOSUS; BOTANICAL IMMUNOMODULATORS; CANCER ADJUVANT; CYP3A4 INHIBITION; HERB-DRUG INTERACTIONS; TINOSPORA CORDIFOLIA; WITHANIA SOMNIFERA;

ASPARAGUS PLANT; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOLOGIC FACTORS; PLANT EXTRACTS; TINOSPORA; WITHANIA;

EID: 84894431553     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735413503551     Document Type: Article

References (40)

1. Verhoef MJ, Vanderheyden LC, Fønnebø V. A whole systems research approach to cancer care: why do we need it and how do we get started?. Integr Cancer Ther. 2006 ; 5: 287-292
2. Patwardhan B, Gautam M. Botanical immunodrugs: scope and opportunities. Drug Discov Today. 2005 ; 10: 495-502
3. Lin Z. Cellular and molecular mechanisms of immuno-modulation by. Ganoderma lucidum. J Pharmacol Sci. 2005 ; 99: 144-153
4. Engdal S, Klepp O, Nilsen OG. Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009 ; 8: 29-36
5. Aapro MS, Walko CM. Aprepitant: drug-drug interactions in perspective. Ann Oncol. 2010 ; 21: 2316-2323
6. Mrozikiewicz PM, Bogacz A, Karasiewicz M, et al. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine. 2010 ; 17: 830-833
7. Shord SS, Shah K, Lukose A. Drug-botanical interactions: a review of the laboratory, animal, and human data for 8 common botanicals. Integr Cancer Ther. 2009 ; 8: 208-227
8. Malati CY, Robertson SM, Hunt JD, et al. Influence of Panax ginseng on cytochrome P450 (CYP) 3A and P-glycoprotein (P-gp) activity in healthy participants. J Clin Pharmacol. 2012 ; 52: 932-939
9. Modarai M, Yang M, Suter A, et al. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4). Planta Med. 2010 ; 76: 378-385
10. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).Guidance for industry: botanical drug products. June2004. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070491.pdf. Accessed August 27, 2013.
11. European Medicine Agency, Committee for Human Medicinal Products (CHMP) guideline on the investigation of drug interactions CPMP/EWP/560/95/Rev.2010. http://www.ema.europa.eu. Accessed August 27, 2013.
12. Balasubramani SP, Patwardhan B. Plant-based Rasayana drugs from Ayurveda. Chin J Integr Medicine. 2011 ; 17: 88-94
13. Diwanay S, Gautam M, Patwardhan B. Cytoprotection and immunomodulation in cancer therapy. Curr Med Chem Anticancer Agents. 2004 ; 4: 479-490
14. Diwanay S, Chitre D, Patwardhan B. Immunoprotection by botanical drugs in cancer chemotherapy. J Ethnopharmacol. 2004 ; 90: 49-55
15. Jagetia GC, Rao SK. Evaluation of the antineoplastic activity of guduchi (Tinospora cordifolia) in Ehrlich ascites carcinoma bearing mice. Biol Pharm Bull. 2006 ; 29: 460-466
16. Jagetia GC, Nayak V, Vidyasagar MS. Evaluation of the antineoplastic activity of guduchi (Tinospora cordifolia) in cultured HeLa cells. Cancer Lett. 1998 ; 127: 71-82
17. Sun Y, Xun K, Wang Y, Chen X. A systematic review of the anticancer properties of berberine, a natural product from Chinese herbs. Anticancer Drugs. 2009 ; 20: 757-769
18. Patil D, Gautam M, Jadhav SS, Patwardhan B.. Paper presented at: International Seminar on Herbal Drug Research: Present and Future Prospects ; Ooty, Tamil Nadu, India ;..
19. Patil D, Gautam M, Jadhav U, et al. Physicochemical stability and biological activity of Withania somnifera extract under real-time and accelerated storage conditions. Planta Med. 2010 ; 76: 481-488
20. Patil D, Gautam M, Mishra S, et al. Quantitative determination of protoberberine alkaloids in Tinospora cordifolia by RP-LC-DAD method. Chromatographia. 2010 ; 71: 341-345
21. Lee CA, Kadwell SH, Kost TA, Serabjit-Singh CJ. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4. Arch Biochem Biophys. 1995 ; 319: 157-167
22. Kostrubsky VE, Ramachandran V, Venkataramanan R, et al. The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos. 1999 ; 27: 887-894
23. Li XF, Maa M, Cheng A, et al. Determination of testosterone and its metabolites using liquid chromatography with elevated column temperature and flow-rate gradient. Anal Chim Acta. 2002 ; 457: 165-171
24. Zhang L, Zhang YD, Zhao P, Huang SM. Predicting drug-drug interactions: an FDA perspective. AAPS J. 2009 ; 11: 300-306
25. Hua W, Ding L, Chen Y, et al. Determination of berberine in human plasma by liquid chromatography-electrospray ionization-mass spectrometry. J Pharm Biomed Anal. 2007 ; 44: 931-937
26. Von Moltke LL, Greenblatt DJ, Duan SX, et al. In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction. J Clin Pharmacol. 1994 ; 34: 1222-1227
27. Racha JK, Zhao ZS, Olejnik N, et al. Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab Pharmacokinet. 2003 ; 18: 128-138
28. Turpeinen M, Korhonen LE, Tolonen A, et al. Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharm Sci. 2006 ; 29: 130-138
29. Khaliq Y, Gallicano K, Venance S, et al. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and cerebrospinal fluid from patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2000 ; 68: 637-646
30. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004 ; 54: 290-294
31. Saha S, Ghosh S. Tinospora cordifolia: one plant, many roles. Anc Sci Life. 2012 ; 31: 151-159
32. Jagetia GC, Rao SK. Evaluation of cytotoxic effects of dichloromethane extract of Guduchi (Tinospora cordifolia Miers ex Hook F & THOMS) on cultured HeLa cells. Evid Based Complement Alternat Med. 2006 ; 3: 267-272
33. Nair PK, Rodriguez S, Ramachandran R, et al. Immune stimulating properties of a novel polysaccharide from the medicinal plant Tinospora cordifolia. Int Immunopharmacol. 2004 ; 4: 1645-1659
34. Su CR, Ueng YF, Dung NX, et al. Cytochrome P3A4 inhibitors and other constituents of Fibraurea tinctoria. J Nat Prod. 2007 ; 70: 1930-1933
35. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol. 2005 ; 45: 422-433
36. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005 ; 4: 825-833
37. Xin HW, Wu XC, Li Q, et al. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol. 2006 ; 28: 25-29
38. Wu X, Li Q, Xin H, et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005 ; 61: 567-572
39. Gurley BJ, Swain A, Hubbard MA, et al. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther. 2008 ; 83: 61-69
40. Butterweck V, Derendorf H. Potential of pharmacokinetic profiling for detecting herbal interactions with drugs. Clin Pharmacokinet. 2008 ; 47: 383-397